GlassScriptPhysician profile
Richard David Grebosky
NPI 1912960394
$17,296.43
in general payments reported to CMS, 2019-2025
27 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $479 · 2021: $2,181 · 2022: $680 · 2023: $550 · 2024: $210 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $12K · Food and Beverage: $512 · Travel and Lodging: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $11,647.50 |
| Food and Beverage | $511.63 |
| Travel and Lodging | $249.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $11,709.28 | 2019-2025 | Grafix Pl |
| Treace Medical Concepts, INC. | $4,532.86 | 2019-2023 | |
| Horizon Therapeutics Plc | $146.69 | 2019-2023 | Krystexxa |
| Depuy Synthes Sales INC. | $126.08 | 2019 | |
| Exact Sciences Corporation | $80.14 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $72.57 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $63.64 | 2024 | Krystexxa |
| Ossio INC | $49.05 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.74 | 2021-2024 | Xifaxan |
| Midmark Corporation | $42.48 | 2021 | |
| Abbott Laboratories | $41.83 | 2022 | |
| Paratek Pharmaceuticals, INC. | $40.01 | 2023 | Nuzyra |
| Tactile Systems Technology INC | $39.43 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Novo Nordisk INC | $36.86 | 2021-2023 | |
| Grt US Holding, INC. | $33.86 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $28.10 | 2024 | Qutenza |
| Osiris Therapeutics INC. | $25.80 | 2019 | |
| Innovation Technologies INC | $23.49 | 2020 | |
| Organogenesis INC. | $21.49 | 2023 | Puraply |
| Merck Sharp & Dohme LLC | $21.23 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $20.81 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.69 | 2023 | Ultomiris |
| Seqirus USA INC | $18.12 | 2022 | |
| Kerecis Limited | $17.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.00 | 2024 | |
| Sanofi-Aventis U.S. LLC | $11.48 | 2021 | |
| Orthofix Medical, INC. | $7.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Grebosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.